Inovum

Olmesartan medoxomil / amlodipine, the active ingredient in Inovum, is a Angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) presented as an oral tablet for oral use. It treats hypertension in adult patients and helps lower elevated blood pressure. GNH USA supplies Inovum as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inovum, a combination of an ARB and a calcium channel blocker, is indicated for the management of hypertension.

- Hypertension (essential): lowers systolic and diastolic blood pressure in adults with primary hypertension. - Hypertension (insufficient control with monotherapy): provides additional blood pressure reduction when single‑agent therapy does not achieve target. - Hypertension (with cardiovascular risk): contributes to overall risk management in patients with hypertension and additional cardiovascular risk factors.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Peripheral edema, especially of the ankles. - Flushing or warmth sensation. - Fatigue. - Palpitations.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue, or airway. - Severe hypotension. - Significant renal impairment or sudden rise in serum creatinine. - Hepatic dysfunction with elevated transaminases. - Neutropenia or other blood dyscrasias. - Severe allergic reactions such as Stevens‑Johnson syndrome.

Inovum should be used with caution and under medical supervision. - Monitor blood pressure regularly: adjust therapy if target values are not reached. - Assess renal function before initiation and periodically thereafter. - Avoid use in pregnancy: classified as Category D due to fetal risk. - Use cautiously in hepatic impairment: dose adjustment may be required. - Review concomitant potassium‑sparing agents: risk of hyperkalaemia. - Store at room temperature: keep in the original pack, protect from moisture and light.

Inovum may interact with several medicines.

Major Interactions (Avoid): - ACE inhibitors or other ARBs: increased risk of renal impairment and hyperkalaemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise amlodipine levels, leading to hypotension.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt the antihypertensive effect of Inovum. - Simvastatin or other CYP3A4 substrates: increased statin concentrations raise the risk of myopathy.